Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aliskiren. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN known ✓ | P00797 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aliskiren SCHEMBL3476540 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL3397036 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL2478013 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL29521564 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL455490 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL3476535 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL13320734 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL13351616 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL7965529 | 1.00 | REN (1.00) | REN | |
| Aliskiren SCHEMBL6854403 | 1.00 | REN (1.00) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | claimed |
| EP-2773351-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013066718-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | HSD11B1, HSD11B2, CYP11B1 | REN 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.